# OnCo record rejuv-second-from-clone-to-disease (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/rejuv-second-from-clone-to-disease/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "rejuv-second-from-clone-to-disease" ;
  schema:name "From a clone in the blood to a leukaemia: what is known, and what is done"@en ;
  schema:alternateName "CHIP progression"@en, "Clonal haematopoiesis and therapy-related myeloid neoplasm"@en, "Clonal haematopoiesis risk score"@en ;
  schema:description "Chemotherapy and radiotherapy select for blood stem cells carrying particular mutations, and in a small minority one of those clones becomes a leukaemia. The useful question is not whether a clone is there but whether it will progress: most never do, and nothing has been shown to stop one that does."@en ;
  schema:url <https://onco.cc/terms/rejuv-second-from-clone-to-disease/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Clonal_hematopoiesis> ;
  schema:citation <https://doi.org/10.1016/S1470-2045(16)30626-X>, <https://doi.org/10.1056/evidoa2200310>, <https://doi.org/10.1001/jamaoncol.2018.5625> ;
  onco:tag "rejuvenation", "survivorship", "second-cancers", "blood", "biomarker" ;
  onco:related <https://onco.cc/technologies/rejuv-age-clonal-haematopoiesis-after-therapy/>, <https://onco.cc/terms/rejuv-second-alkylating-agents-and-myeloid-neoplasms/>, <https://onco.cc/terms/rejuv-second-topoisomerase-inhibitors-short-latency/>, <https://onco.cc/terms/rejuv-second-cancers-overview/> ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/mds/>, <https://onco.cc/cancers/aml-secondary/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/wes-wgs/>, <https://onco.cc/technologies/survivorship-care-plan/> ;
  onco:pathways <https://onco.cc/pathways/clonal-haematopoiesis/> ;
  onco:terms <https://onco.cc/terms/secondary-malignancy/>, <https://onco.cc/terms/late-effects/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-survivorship/>, <https://onco.cc/bottlenecks/b-overdiagnosis/> .